Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

TB-500 vs GHK-Cu

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: favors GHK-Cu

GHK-Cu has the better evidence and the easier legal path for its main use: small human cosmetic studies report benefits from topical GHK-Cu creams in aged skin, though its one small randomized trial, after laser resurfacing, found no objective benefit, and those creams are sold lawfully as cosmetics. TB-500 is a synthetic 7 amino acid fragment of thymosin beta-4, and FDA says the two are not the same substance. No study has given TB-500 to humans: the strong rodent wound and cardiac data and the human eye drop trial that missed its primary endpoints all used full-length thymosin beta-4, and TB-500 itself has not been tested that way. Both lack human data for injection, and TB-500 is named on the WADA Prohibited List while GHK-Cu is not.

Verified: Verified Oct 28, 2026
TB-500SponsoredFrom Bodybuilding Peptides
Glow blend (GHK-Cu / BPC-157 / TB-500)SponsoredFrom Bodybuilding Peptides

Which is better, TB-500 or GHK-Cu?

GHK-Cu is graded human RCT on one small randomized trial of topical GHK-Cu after laser resurfacing, which found no objective benefit, alongside small topical cosmetic studies that report improvements, and topical products are lawful without a prescription. TB-500 is graded animal only: FDA's July 2026 briefing found no article in which TB-500 was given to humans. The randomized eye drop trial often cited for it, in dry eye, used full-length thymosin beta-4 and did not meet its primary endpoints, and FDA says thymosin beta-4 and TB-500 are not the same substance, so that trial does not count toward TB-500's grade. On regulatory status, injectable TB-500 is covered by HHS's October 28, 2026 draft enforcement discretion policy for single-ingredient compounding on a patient-specific prescription (FDA's drug center recommended against listing; the advisory committee voted in favor, per HHS's Appendix B), while injectable GHK-Cu was not reviewed and is not covered, but the draft does not change the evidence gap, and TB-500 is explicitly banned in sport. [3] [6] [9] [10] [11] [14] [17] [19]

How do TB-500 and GHK-Cu compare?

TB-500 and GHK-Cu compared by dimension
DimensionTB-500GHK-CuFavored
What it is [4] [7] [14]Synthetic 7 amino acid fragment (acetylated LKKTETQ) of thymosin beta-4, a 43 amino acid protein; FDA says the two are not the same substance. Sellers often describe TB-500 as thymosin beta-4, so what a given product contains is not verified.Naturally occurring copper binding tripeptide (glycyl-histidyl-lysine) found in human plasma, saliva, and urine.
Evidence grade [3] [6] [13] [14] [17]Animal only. No study has given TB-500 to humans. The human trials often cited for it used full-length thymosin beta-4: a phase 2 eye drop trial (72 adults, dry eye) missed both primary endpoints, and phase 1 intravenous studies in healthy volunteers tested safety only.Human RCT for topical use: one small randomized trial after laser resurfacing (13 completers) found no objective benefit; other data are small cosmetic studies of creams in aged skin, cited through reviews. No human data for injection.
Strongest animal evidence [1] [2] [5] [14] [15] [16]For TB-500 itself: a horse study and a rat study of how it is absorbed and broken down, and a cell study in which it did not close scratch wounds. The well-known results (rat wounds with reepithelialization up 42% at day 4 and 61% at day 7; improved cardiac function after coronary ligation in mice) used full-length thymosin beta-4, and TB-500 has not been tested that way.Faster skin wound healing in rats, mice, pigs, and dogs, plus hair follicle, bone, and gut healing in rodents.
Proposed mechanism [2] [4] [7] [14]Contains the actin binding region of thymosin beta-4 and is hypothesized, not shown, to share its role. The mechanisms usually quoted (binding G-actin to drive cell migration, activating the ILK and Akt cell survival pathway, reducing inflammation and scarring in animals) were documented with full-length thymosin beta-4.Delivers copper to cells, recruits repair cells, and increases collagen, elastin, and glycosaminoglycan synthesis; suppresses NF-kB and TNF-alpha in models.
Routes with human data [3] [6] [13] [14]None. No study has given TB-500 to humans by any route; the eye drop and intravenous trials used full-length thymosin beta-4.Topical cream or serum only. Subcutaneous injection as sold has no human data.
FDA and compounding status [8] [9] [10] [19] [20]Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection only) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B).Injectable nomination withdrawn, so it is in no 503A category, not on the bulks list, not reviewed by PCAC, and not covered by HHS's October 2026 draft policy. Topical is a lawful cosmetic ingredient when no drug claims are made; non-injectable GHK-Cu is in 503A Category 1 (in FDA review).
WADA status [11] [12]Prohibited at all times under S2; thymosin beta-4 and TB-500 are named on the list.Not named. Injected GHK-Cu may fall under S0 as a non-approved substance, so its status is unclear; topical cosmetic use is not a recognized concern.
Typical cost [8] [10] [19]No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price.Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. No lawful compounded price for injectable GHK-Cu, which is not on the 503A bulks list and is not covered by HHS's draft policy.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

TB-500 and GHK-Cu: grade, status, and cost
AttributeTB-500GHK-Cu
ClassSynthetic N-acetylated 7 amino acid fragment (amino acids 17 to 23, LKKTETQ) of thymosin beta-4, a 43 amino acid actin sequestering proteinNaturally occurring tripeptide (glycyl-histidyl-lysine) complexed with copper(II); found in human plasma, saliva, and urine
What it isSynthetic 7 amino acid fragment of thymosin beta-4. No human study of TB-500 itself; the human trials used the full-length protein. WADA banned.Copper binding peptide used in skin cosmetics; one small randomized topical trial found no objective benefit. Injectable form is unapproved and untested.
EvidenceEvidence: Animal-only evidenceEvidence: Human RCT evidence
FDA statusRegulatory: HHS interim policy (draft)Regulatory: Nomination withdrawn
CompoundingTB-500 is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA's withdrawn list names it Thymosin beta-4, fragment (LKKTETQ). FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026 for wound healing: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds TB-500 when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add TB-500 to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.GHK-Cu has two regulatory tracks. As a cosmetic ingredient in topical products it can be sold without FDA premarket approval, as long as the product makes no drug claims. As a drug it is not FDA approved. For compounding, FDA treats it by route. GHK-Cu for non-injectable routes is in 503A Category 1 (under evaluation). Under FDA's interim policy, FDA does not intend to act against a 503A pharmacy or physician that compounds it for an identified patient on a prescription, if the ingredient comes from a registered manufacturer with a valid certificate of analysis and all other 503A conditions are met. GHK-Cu for injectable routes was in Category 2 and is now on FDA's list of withdrawn nominations. That list is outside any category and outside the interim policy, so as of the last verification date a 503A pharmacy has no federal basis to compound injectable GHK-Cu from bulk. FDA has said it intends to consult the Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027. FDA has also warned that 'research use only' labels do not make a product lawful when it is intended for use in people.
WADAWADA: WADA prohibitedWADA: WADA status unclear
RoutesSubcutaneous or intramuscular injection (as sold, and the routes FDA evaluated), Subcutaneous injection in horses and intraperitoneal injection in rats (TB-500 metabolism studies), Intravenous infusion, topical application, and eye drops (human trials of full-length thymosin beta-4, not TB-500)Topical cream or serum (cosmetic use, the only form with human data), Subcutaneous injection (as sold; no human data), Topical, intraperitoneal, and systemic (animal studies)
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient TB-500 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. There is no lawful compounded price for injectable GHK-Cu: it is off 503A Category 2 but is not on the 503A bulks list and was not recommended by PCAC in July 2026. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Last verified

Has TB-500 been tested directly against GHK-Cu?

No published trial has compared TB-500 and GHK-Cu directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do TB-500 and GHK-Cu cost?

Typical cost of TB-500 and GHK-Cu
DimensionTB-500GHK-Cu
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient TB-500 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. There is no lawful compounded price for injectable GHK-Cu: it is off 503A Category 2 but is not on the 503A bulks list and was not recommended by PCAC in July 2026. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Price detailTB-500 price by channelGHK-Cu price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the TB-500 page and the GHK-Cu page.

Are TB-500 and GHK-Cu combined?

TB-500 and GHK-Cu are sold together in the premixed blends below. No study has tested the combination, and a mix is only as lawful as its least lawful ingredient. The blend pages cover what is in each product, the evidence for each ingredient, and legal status.

  • GLOW: No federal basis to compound.
  • KLOW: No federal basis to compound.

Frequently asked questions

Which is better for wound healing, TB-500 or GHK-Cu?

GHK-Cu accelerates wound healing in animals across several species and has human topical cosmetic studies. TB-500 itself has no wound healing study in animals or people: the strong rat wound data belong to full-length thymosin beta-4, which FDA says is not the same substance as TB-500. Neither has a human trial of the injectable form for wounds. For a real wound, standard wound care comes first. [1] [5] [6] [14]

Does the thymosin beta-4 eye drop trial support injected TB-500?

No. It tested thymosin beta-4 eye drops for dry eye in 72 adults, and neither primary endpoint beat placebo. That is a different substance, route, and use: TB-500 is a 7 amino acid fragment of thymosin beta-4, FDA says the two are not the same substance, and no study has given TB-500 to humans. [3] [4] [14]

Can athletes use either one?

TB-500 is explicitly prohibited: thymosin beta-4 and TB-500 are named under S2 of the WADA Prohibited List. GHK-Cu is not named, but injected use of a non-approved substance may fall under S0, so tested athletes should avoid the injectable. [11] [12]

Which is easier to get legally?

Topical GHK-Cu, which is sold over the counter as a cosmetic ingredient. Neither injectable is on the bulks list. TB-500 is covered by HHS's October 28, 2026 draft enforcement discretion policy, which says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection) on a patient-specific prescription, when sourcing, testing, and adverse event reporting conditions are met. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. Injectable GHK-Cu is not covered: its nomination was withdrawn and it was not reviewed. Research chemical vials of either sold for human use are still unapproved drugs, and state law still applies. [8] [9] [10] [18] [19] [20]

Conditions studied

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999PubMed 10469335, 1999
  2. [2]Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004PubMed 15565145, 2004
  3. [3]Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial. Clin Ophthalmol 2015PubMed 26056426, 2015
  4. [4]Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012PubMed 22074294, 2012
  5. [5]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018PubMed 29986520, 2018
  6. [6]Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015PubMed 26236730, 2015
  7. [7]Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008PubMed 18644225, 2008
  8. [8]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  9. [9]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  10. [10]FDA: Is it a cosmetic, a drug, or both? (or is it soap?)FDA, 2024

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). TB-500 vs GHK-Cu: evidence, cost, and legality. https://peptideagent.ai/compare/tb-500-vs-ghk-cu
HTML link
<a href="https://peptideagent.ai/compare/tb-500-vs-ghk-cu">TB-500 vs GHK-Cu: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.